📰 Cell Cycle News
Page 8 - Cell Cycle News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Cell Cycle. Real-time updates on events, politics, business and more.
April 11, 2022
/PRNewswire/ -- Antengene Corporation Limited ("Antengene" SEHK: 6996.HK), a leading innovative, global biopharmaceutical company dedicated to discovering,...
April 9, 2022
NATICK, Mass.--(BUSINESS WIRE)--PIC Therapeutics, Inc., a biotechnology company pioneering the discovery and development of first-in-mechanism, first-in-class allosteric therapies targeting eIF4E, today announced it will present pre-clinical data on the company’s eIF4E program for ER+ breast cancer in a poster at th...
April 9, 2022
PIC Therapeutics, Inc., a biotechnology company pioneering the discovery and development of first-in-mechanism, first-in-class allosteric therapies ta
April 5, 2022
Researchers profiled cardiac tissue transcriptomes of COVID-19 patients.
March 22, 2022
DNA is often likened to a blueprint. The particular sequence of As, Cs, Gs, and Ts in DNA provides information for building an organism.
March 9, 2022
/PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB),...
March 9, 2022
SUZHOU, China and ROCKVILLE, Md., March 9, 2022 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that the results from six preclinical studies of the company's five drug candidates: the Bcl-2 inhibitor lisaftoclax (APG-2575) and the MDM2-p53 inhibitor alrizomadlin (APG-115), two...
March 9, 2022
/PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB),...
March 7, 2022
A new study discusses the possible etiopathogenetic mechanisms associated with diabetes that could enhance the severity of COVID-19.
February 26, 2022
An international team of researchers, led by the University of Massachusetts Amherst, recently announced in the journal Current Biology that an amoeba called Naegleria has evolved more distinct sets of tubulins, used for specific cellular processes, than previously thought.